BMI View: South Korea continues to invest in pharmaceutical research and development (R&D). In one of
the latest developments in this area, the South Korea Health Ministry announced in July 2013 that it will
spend a total of KRW10trn (US$8.9bn) on projects to develop ..."
BMI View: The fourth quarter of 2012 brought positive revenue growth for large domestic
pharmaceutical firms in South Korea, the first positive result following many erratic price cuts that had
been instituted since 2011. We highlight a slow positive change in sentiment in the ..."
GBI Research’s new report, “South Korea Pharmaceutical Market Outlook 2013” provides in-depth analysis of the trends, issues and challenges facing the South Korean pharmaceutical market. The report also provides competitive benchmarking for the country’s leading pharmaceutical co ..."
BMI View: We expect the South Korean government to continue its pharmaceutical price reduction policy, as it has generated significant savings to public-sector budgets. Indeed, according to the South Korea National Health Insurance Review And Assessment Service, the public spendi ..."
Given the commitment to innovation in both the public and the private sector in the country, South Korea will continue to be one of the key leaders in research and development (R&D) in the Asia Pacific region. However, we continue to see challenges to multinational companies ..."